Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credits: NatGeo/Chris Hemsworth Instagram
Talking about things makes you feel better, and the Thor star Chris Hemsworth is right at it. Now 42, he is opening up about his father, Craig's diagnosis of Alzheimer's and have seen the corrosive effects on his memory and perception already. He is now making the best of it, by having it all documented on film. While he was in the middle of making National Geographic longevity series Limitless, he learned that he too carried two copies of the Alzheimer's signifying gene APOE4, one from each parent. Back then he confronted this on camera, while on shoot, and this feels like a great idea for him to do it again on A Road Trip To Remember, an hour-long documentary that will air on NatGeo.
“There was apprehension about how this would be portrayed,” Hemsworth admits. “I asked Dad what he felt, and he was actually enthusiastic. He wanted to do it.”
The Australian actor is now taking steps to stay mentally and physically fit, especially after knowing that he is predisposed for Alzheimer's disease.
Chris, who shares three children with wife Elsa Pataky, says his father's struggles have made him reflect deeply on how he lives. Some hardships in life, he notes, simply can’t be avoided.
“For me, the biggest takeaway was the comfort crisis we face,” he says, as reported in Esquire. “We settle for what’s familiar, even when it’s wrong, because the unknown feels scarier. But pushing against that is where growth happens.”
His father’s reaction to the diagnosis has also taught him that even a grim prognosis can be approached with courage. “It causes fear, but it’s also a reminder not to take anything for granted,” Hemsworth says. “While he can, Dad wants to capture as many memories as possible.”
At the time of filming, Craig’s symptoms were sporadic—some memory lapses, moments of confusion, but overall lucidity remained. Alzheimer’s, however, does not improve with time. Knowing this, the father-son duo set out on a cross-country motorbike trip across Australia.
Guided only by a fading photograph and half-recalled memories, they attempted to reconnect with moments that shaped their family’s early years.
The documentary also explores reminiscence therapy, guided by Dr. Suraj Samtani from the Centre for Healthy Brain Ageing at the University of Sydney. The technique uses personal memories, photos, and familiar environments to stimulate the hippocampus, the part of the brain most affected by Alzheimer’s.
“One-on-one time with Dad was special,” Chris says. “Growing up, it was always all of us together.”
For Hemsworth, the experience has made one truth clear: the importance of connection.
“It became less about the science and more about the moments together,” he says. “Whether it’s 20 years or 20 days, hold on to every moment. Connect deeply, as often as you can.”
Credits: GEMINI
President Trump's noticeably raspy voice drew attention during a meeting with the White House task force on the FIFA World Cup 2026 on Monday, when a reporter asked if he was feeling well. Trump replied, "I feel great. I was shouting at people because they were being foolish about something related to trade and a country, and I straightened it out, but I lost my temper with them." This has reignited discussions about Donald Trump's health.
Trump’s hoarse voice caught attention as he explained it came from raising his voice at foreign leaders over his favorite topic: trade and tariffs. He sounded a bit rough during a November 17 Oval Office event, where he spoke to reporters about the U.S. hosting plans for the 2026 FIFA World Cup, as per USA Today.
"I feel great," Trump said when asked about his raspy tone. "I was shouting at people because they were stupid about something to do with trade in a country, and I fixed it. But I lost my temper with them." He added, "A country tried to renegotiate the terms of their trade deal, and I wasn’t happy." When pressed on which country, Trump refused to answer, saying, "Why would I say that to you?"
Trump’s health has been under the microscope during his second term, particularly dark spots noticed on his hand, which he attributes to taking aspirin regularly and frequent handshakes. The White House reported he recently had an MRI as part of his annual physical, which Trump described as “standard,” though he admitted he did not know what exactly the doctors were reviewing, as per USA Today.
Earlier this year, it was also disclosed that Trump was diagnosed with a common vein condition, usually not serious with treatment, after he was seen with swollen ankles. At 79, Trump continues to insist his health is excellent.
Trump revealed he had an MRI scan, saying the doctor called it the “best result” they had ever seen in their career. When asked which part of his body was examined, he clarified that it was all part of a “routine annual” physical. “I had no idea what they analyzed, but whatever they analyzed, they analyzed it well,” he said.
In October, Trump told reporters he underwent an MRI at Walter Reed National Military Medical Center during a “very standard” checkup, describing it as routine. When asked if it involved his brain, he said, “Getting an MRI is very standard. What, you think I shouldn’t have it? Other people get it … I had an MRI. The doctor said it was the best result he has ever seen as a doctor.”
While traveling on Air Force One to Florida, the president added, “The other thing I did … as you know … was a very advanced test on mental acuity because I believe a president should do that, and as you probably heard, I aced it.”
Journalist Mehdi Hasan reacted on X, saying: “Donald Trump says he does not know why he had an MRI. How is this not 25th Amendment territory?”
MSNBC co-host Symone D. Sanders Townsend also wrote on X Friday: “This is not routine. Why did the President need an MRI?”
As this marked Trump’s second MRI, questions have emerged about his health. Initially, the White House described his visit to Walter Reed as a “routine yearly checkup,” even though he had already had his yearly physical in April. The president later referred to it as a “semiannual physical.”
Credits: Canva
The FDA on Friday revised the safety information for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy, Elevidys, adding a boxed warning to alert patients and doctors about the risk of severe liver damage and possible death. This highest-level warning outlines the chance of serious liver injury and acute liver failure in people who receive Elevidys, with both complications carrying the possibility of being fatal.
The agency has also limited the therapy’s use to ambulatory Duchenne patients who are at least 4 years old and have a confirmed mutation in the DMD gene. With these changes, Elevidys is no longer permitted for patients who cannot walk.
Duchenne muscular dystrophy (DMD) is a serious inherited condition that leads to steady muscle weakening and loss, affecting boys far more often. It stems from a defect in the dystrophin gene, which prevents the body from making a key protein that protects muscle fibers.
Signs usually show up in early childhood and include trouble walking or climbing, frequent falls and a noticeable waddling walk, according to the Cleveland Clinic.
Gene therapy for Duchenne muscular dystrophy delivers a corrected or shortened form of the dystrophin gene into muscle cells using a modified virus. This allows the cells to produce a working version of the protein. The single intravenous infusion is designed to slow the disease by restoring some dystrophin, with the aim of improving movement and daily functioning. While the FDA has cleared a therapy that creates a reduced “micro-dystrophin,” researchers are still working on ways to provide the full-length gene for potentially stronger results, as noted by the Food and Drug Administration.
Elevidys is a gene-based treatment designed for Duchenne muscular dystrophy. It is given only once and relies on an adeno-associated virus to carry a modified form of the dystrophin gene into the body. This shorter micro-dystrophin version is meant to take the place of the faulty or absent dystrophin that leads to the condition.
The U.S. Food and Drug Administration is tightening control over a Duchenne muscular dystrophy gene therapy after two teenagers died from liver failure linked to the treatment. The agency has restricted Elevidys, made by Sarepta Therapeutics, to boys aged 4 and older who are still able to walk.
It can no longer be given to boys who have already lost the ability to move independently, something that usually occurs around age 12 in Duchenne. A safety review confirmed that both teenagers developed severe liver damage after receiving the infusion and later died.
The FDA is also adding its strongest boxed warning to call attention to the risks of serious liver injury, acute liver failure and death. Sarepta, based in Cambridge, Massachusetts, with offices in several countries, told regulators earlier this year that it had already stopped supplying the therapy to non-ambulatory patients. The company stated that Elevidys has been used in 1,100 patients worldwide.
These updates “will ensure that families and health-care professionals have clear information” to support treatment choices, Louise Rodino-Klapac, Sarepta’s head of research and development, told The New York Times.
The FDA’s new label comes at the end of a difficult year for Sarepta, marked by weak clinical trial results, safety questions surrounding Elevidys and declining sales.
© 2024 Bennett, Coleman & Company Limited